SI-Bone Files Automatic Mixed Securities Shelf
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy SIBN?
SI-Bone files automatic mixed securities shelf
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SIBN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SIBN
Wall Street analysts forecast SIBN stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.230
Low
23.00
Averages
25.17
High
28.00
Current: 16.230
Low
23.00
Averages
25.17
High
28.00
About SIBN
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SI-BONE, Inc. Reports Record Q4 2025 Earnings and Strategic Developments
- Record Performance: SI-BONE achieved a worldwide revenue of $56.3 million in Q4 2025, reflecting a 15% year-over-year growth, with U.S. revenue at $53.5 million, indicating sustained competitive strength and potential for future growth.
- Strategic Partnership: The company entered into a strategic partnership with Smith & Nephew, a leader in orthopedics, aimed at capitalizing on growing physician interest in trauma solutions, significantly expanding market reach and accelerating penetration into the trauma market, which is expected to positively impact revenue.
- New Product Launch: The INTRA Ti, a new addition to the SI Joint Fusion platform, received FDA 510(k) clearance, expected to enhance procedural efficiency in ambulatory surgery centers, further solidifying the company's leadership in innovative products and laying the groundwork for future market expansion.
- Optimistic Financial Outlook: SI-BONE projects worldwide revenue between $228.5 million and $232.5 million for 2026, implying a year-over-year growth of 14% to 16%, while planning investments in key growth areas including new product launches and sales force expansion, demonstrating confidence in future growth prospects.
See More
SI-BONE Q4 Earnings Beat Expectations with Improved Losses
- Earnings Performance: SI-BONE reported a Q4 GAAP EPS of -$0.04, beating expectations by $0.08, indicating a positive trend in the company's profitability improvement.
- Revenue Growth: The company achieved Q4 revenue of $56.3 million, a 14.9% year-over-year increase, aligning with market expectations and demonstrating sustained demand for its products, which bolsters market confidence.
- Rising Operating Expenses: Operating expenses rose 6.2% year-over-year to $47.0 million, primarily driven by commercial activities related to revenue growth and R&D investments for future products, reflecting the company's strategic focus on business expansion.
- Improved Operating Loss: The operating loss improved by 55.2% to $2.5 million in Q4, compared to a loss of $5.5 million in the same period of 2024, showcasing significant progress in cost control and efficiency enhancements.
See More
Smith+Nephew Partners with SI-BONE to Enhance Trauma Solutions
- Distribution Agreement: Smith+Nephew has signed a distribution agreement with SI-BONE, focusing on the iFuse TORQ portfolio, aimed at optimizing the product offerings for fracture fixation procedures and enhancing the company's market position in high-frequency trauma surgeries.
- Innovative Technology Introduction: The iFuse TORQ TNT implant system has received FDA Breakthrough Device Designation, which is expected to provide more effective treatment for fractures compared to traditional screws, potentially significantly improving patient outcomes.
- Economic Benefit Enhancement: iFuse TORQ TNT is eligible for Medicare New Technology Add-on Payment, allowing hospitals to receive up to $4,136 in additional reimbursement per procedure, which enhances the willingness of hospitals to adopt this technology.
- Market Expansion Opportunities: Through the partnership with SI-BONE, Smith+Nephew will expand its product coverage in the trauma sector, deepen collaboration with surgeons, and drive sustainable growth to meet the demands of a high-need market.
See More
SI-BONE to Participate in Annual Health Care Conference
- Conference Participation: SI-BONE will host a management fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026, at 7:30 a.m. PT/10:30 a.m. ET, aimed at showcasing the company's latest advancements in orthopedic solutions.
- Investor Registration Info: Investors can register via the provided link to listen to the conference call, ensuring they stay updated on the company's latest developments and strategic direction, thereby enhancing investor confidence in future growth.
- Live Webcast and Replay: The live audio of the webcast will be available in the
See More
SI-BONE Announces Preliminary Q4 and Full-Year 2025 Revenue Growth
- Quarterly Performance Forecast: SI-BONE anticipates fourth-quarter revenue for FY 2025 to be between $56.2 million and $56.3 million, representing a 15% increase from $49 million last year, indicating strong market demand in the musculoskeletal sector.
- Full-Year Revenue Growth: The company expects total revenue for FY 2025 to range between $200.8 million and $200.9 million, up 20% from $167.18 million in the previous year, reflecting the sustained popularity of its products in both U.S. and international markets.
- U.S. Market Performance: Preliminary U.S. revenue for the fourth quarter is projected to be between $53.3 million and $53.4 million, a 14% increase from $46.9 million a year ago, demonstrating the effectiveness of the company's sales strategy in the U.S. market.
- Cash Flow Position: As of the fourth quarter, SI-BONE reported cash and equivalents of approximately $147.7 million, ensuring financial flexibility for future investments and operations.
See More
SI-Bone Executives Sell Shares for Tax Obligations as Stock Rises 3.65%
- Stock Performance: SI-Bone Inc. shares rose 3.65% to $21.14 in after-hours trading on Tuesday, reflecting strong market confidence, particularly with a 12-month return of 44.48% indicating robust growth.
- Executive Share Sales: CFO Anshul Maheshwari sold 5,229 shares for a total of $102,710.61, demonstrating proactive tax planning by executives while also reflecting their confidence in the company's stock performance.
- Market Capitalization: With a market cap of approximately $885.2 million, SI-Bone's stock is trading at 92.2% of its 52-week high, indicating strong market demand and a solid position in the medical device sector.
- Analyst Ratings: Firms like Truist Securities and Morgan Stanley maintained bullish ratings and raised price targets in December, further bolstering investor confidence and suggesting potential for future growth.
See More
SI-BONE, Inc. Reports Record Q4 2025 Earnings and Strategic Developments
- Record Performance: SI-BONE achieved a worldwide revenue of $56.3 million in Q4 2025, reflecting a 15% year-over-year growth, with U.S. revenue at $53.5 million, indicating sustained competitive strength and potential for future growth.
- Strategic Partnership: The company entered into a strategic partnership with Smith & Nephew, a leader in orthopedics, aimed at capitalizing on growing physician interest in trauma solutions, significantly expanding market reach and accelerating penetration into the trauma market, which is expected to positively impact revenue.
- New Product Launch: The INTRA Ti, a new addition to the SI Joint Fusion platform, received FDA 510(k) clearance, expected to enhance procedural efficiency in ambulatory surgery centers, further solidifying the company's leadership in innovative products and laying the groundwork for future market expansion.
- Optimistic Financial Outlook: SI-BONE projects worldwide revenue between $228.5 million and $232.5 million for 2026, implying a year-over-year growth of 14% to 16%, while planning investments in key growth areas including new product launches and sales force expansion, demonstrating confidence in future growth prospects.
See More
SI-BONE Q4 Earnings Beat Expectations with Improved Losses
- Earnings Performance: SI-BONE reported a Q4 GAAP EPS of -$0.04, beating expectations by $0.08, indicating a positive trend in the company's profitability improvement.
- Revenue Growth: The company achieved Q4 revenue of $56.3 million, a 14.9% year-over-year increase, aligning with market expectations and demonstrating sustained demand for its products, which bolsters market confidence.
- Rising Operating Expenses: Operating expenses rose 6.2% year-over-year to $47.0 million, primarily driven by commercial activities related to revenue growth and R&D investments for future products, reflecting the company's strategic focus on business expansion.
- Improved Operating Loss: The operating loss improved by 55.2% to $2.5 million in Q4, compared to a loss of $5.5 million in the same period of 2024, showcasing significant progress in cost control and efficiency enhancements.
See More
Smith+Nephew Partners with SI-BONE to Enhance Trauma Solutions
- Distribution Agreement: Smith+Nephew has signed a distribution agreement with SI-BONE, focusing on the iFuse TORQ portfolio, aimed at optimizing the product offerings for fracture fixation procedures and enhancing the company's market position in high-frequency trauma surgeries.
- Innovative Technology Introduction: The iFuse TORQ TNT implant system has received FDA Breakthrough Device Designation, which is expected to provide more effective treatment for fractures compared to traditional screws, potentially significantly improving patient outcomes.
- Economic Benefit Enhancement: iFuse TORQ TNT is eligible for Medicare New Technology Add-on Payment, allowing hospitals to receive up to $4,136 in additional reimbursement per procedure, which enhances the willingness of hospitals to adopt this technology.
- Market Expansion Opportunities: Through the partnership with SI-BONE, Smith+Nephew will expand its product coverage in the trauma sector, deepen collaboration with surgeons, and drive sustainable growth to meet the demands of a high-need market.
See More
SI-BONE to Participate in Annual Health Care Conference
- Conference Participation: SI-BONE will host a management fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026, at 7:30 a.m. PT/10:30 a.m. ET, aimed at showcasing the company's latest advancements in orthopedic solutions.
- Investor Registration Info: Investors can register via the provided link to listen to the conference call, ensuring they stay updated on the company's latest developments and strategic direction, thereby enhancing investor confidence in future growth.
- Live Webcast and Replay: The live audio of the webcast will be available in the
See More
SI-BONE Announces Preliminary Q4 and Full-Year 2025 Revenue Growth
- Quarterly Performance Forecast: SI-BONE anticipates fourth-quarter revenue for FY 2025 to be between $56.2 million and $56.3 million, representing a 15% increase from $49 million last year, indicating strong market demand in the musculoskeletal sector.
- Full-Year Revenue Growth: The company expects total revenue for FY 2025 to range between $200.8 million and $200.9 million, up 20% from $167.18 million in the previous year, reflecting the sustained popularity of its products in both U.S. and international markets.
- U.S. Market Performance: Preliminary U.S. revenue for the fourth quarter is projected to be between $53.3 million and $53.4 million, a 14% increase from $46.9 million a year ago, demonstrating the effectiveness of the company's sales strategy in the U.S. market.
- Cash Flow Position: As of the fourth quarter, SI-BONE reported cash and equivalents of approximately $147.7 million, ensuring financial flexibility for future investments and operations.
See More
SI-Bone Executives Sell Shares for Tax Obligations as Stock Rises 3.65%
- Stock Performance: SI-Bone Inc. shares rose 3.65% to $21.14 in after-hours trading on Tuesday, reflecting strong market confidence, particularly with a 12-month return of 44.48% indicating robust growth.
- Executive Share Sales: CFO Anshul Maheshwari sold 5,229 shares for a total of $102,710.61, demonstrating proactive tax planning by executives while also reflecting their confidence in the company's stock performance.
- Market Capitalization: With a market cap of approximately $885.2 million, SI-Bone's stock is trading at 92.2% of its 52-week high, indicating strong market demand and a solid position in the medical device sector.
- Analyst Ratings: Firms like Truist Securities and Morgan Stanley maintained bullish ratings and raised price targets in December, further bolstering investor confidence and suggesting potential for future growth.
See More
